Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin plus Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Adenocarcinoma
NCT02993731Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of napabucasin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sumitomo Pharma America. Started Dec 2016; status: completed.
02
Drugs
napabucasin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02993731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993731.